{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:04:38Z","timestamp":1783184678498,"version":"3.54.6"},"reference-count":91,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Recently, homologous recombination deficiency (HRD) has become a new target for hereditary cancers. Molecular-based approaches for hereditary cancers in the clinical setting have been reviewed. In particular, the efficacy of the PARP inhibitor has been considered by several clinical trials for various kinds of hereditary cancers. This indicates that the PARP inhibitor can be effective for any kind of BRCA mutated cancers, regardless of the organ-specific cancer. Homologous recombination deficiency (HRD) has become a new target for hereditary cancers, indicating the necessity to confirm the status of HRD-related genes. ARID1A, ATM, ATRX, PALB2, BARD1, RAD51C and CHEK2 are known as HRD-related genes for which simultaneous examination as part of panel testing is more suitable. Both surgical and medical oncologists should learn the basis of genetics including HRD. An understanding of the basic mechanism of homologous repair recombination (HRR) in BRCA-related breast cancer is mandatory for all surgical or medical oncologists because PARP inhibitors may be effective for these cancers and a specific strategy of screening for non-cancers exists. The clinical behavior of each gene should be clarified based on a large-scale database in the future, or, in other words, on real-world data. Firstly, HRD-related genes should be examined when the hereditary nature of a cancer is placed in doubt after an examination of the relevant family history. Alternatively, HRD score examination is a solution by which to identify HRD-related genes at the first step. If lifetime risk is estimated at over 20%, an annual breast MRI is necessary for high-risk screening. However, there are limited data to show its benefit compared with BRCA. Therefore, a large-scale database, including clinical information and a long-term follow-up should be established, after which a periodical assessment is mandatory. The clinical behavior of each gene should be clarified based on a large-scale database, or, in other words, real-world data.<\/jats:p>","DOI":"10.3390\/curroncol32020090","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T08:57:46Z","timestamp":1738832266000},"page":"90","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Causative Genes of Homologous Recombination Deficiency (HRD)-Related Breast Cancer and Specific Strategies at Present"],"prefix":"10.3390","volume":"32","author":[{"given":"Seigo","family":"Nakamura","sequence":"first","affiliation":[{"name":"Institute for Clinical Genetics and Genomics, Showa University, Tokyo 142-8555, Japan"},{"name":"Division of Breast Surgical Oncology, Department of Surgery, Showa University, Tokyo 142-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9991-0228","authenticated-orcid":false,"given":"Yasuyuki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Institute for Clinical Genetics and Genomics, Showa University, Tokyo 142-8555, Japan"},{"name":"Division of Breast Surgical Oncology, Department of Surgery, Showa University, Tokyo 142-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7723-2357","authenticated-orcid":false,"given":"Sayoko","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Institute for Clinical Genetics and Genomics, Showa University, Tokyo 142-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer Risks Associated with BRCA1 and BRCA2 Pathogenic Variants","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN Guidelines Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. 2.2024 ed. USA","volume":"21","author":"Daly","year":"2023","journal-title":"J. Natl. Compr. Cancer Network"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1148\/radiol.2020191453","article-title":"Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression","volume":"296","author":"Bismeijer","year":"2020","journal-title":"Radiology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jamaoncol.2020.2922","article-title":"Cost-effectiveness of Breast Cancer Screening with Magnetic Resonance Imaging for Women at Familial Risk","volume":"6","author":"Geuzinge","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, D., Pires, A.S., Marques, I.A., Gomes, I., Sousa, G., Botelho, M.F., and Abrantes, A.M. (2022). An Overview on Radiation Sensitivity in Hereditary Breast and Ovarian Cancer Syndrome. Cancers, 14.","DOI":"10.3390\/cancers14133254"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2214\/AJR.21.27022","article-title":"MRI Screening of BRCA Mutation Carriers: Comparison of Standard Protocol and Abbreviated Protocols with and Without T2-Weighted Images","volume":"218","author":"Naranjo","year":"2022","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_10","first-page":"Cd012464","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers","volume":"177","author":"Jager","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10689-020-00188-z","article-title":"Improving primary care identification of familial breast cancer risk using proactive invitation and decision support","volume":"20","author":"Qureshi","year":"2021","journal-title":"Fam. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-018-05116-5","article-title":"Customized breast cancer risk assessment in an ambulatory clinic: A portal for identifying women at risk","volume":"175","author":"Weiss","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41523-020-0163-1","article-title":"Prevalence of disease-causing genes in Japanese patients with BRCA1\/2-wildtype hereditary breast and ovarian cancer syndrome","volume":"6","author":"Kaneyasu","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1038\/s41467-018-06581-8","article-title":"Germline pathogenic variants of 11 breast cancer genes in 7051 Japanese patients and 11,241 controls","volume":"9","author":"Momozawa","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bellhouse, S., Hawkes, R.E., Howell, S.J., Gorman, L., and French, D.P. (2021). Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours. Cancers, 13.","DOI":"10.3390\/cancers13164150"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1002\/cncr.33767","article-title":"Performance of the IBIS\/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women\u2019s Health Initiative","volume":"127","author":"Kurian","year":"2021","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: A comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000441714","article-title":"Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium","volume":"19","author":"Nakamura","year":"2016","journal-title":"Public Health Genom."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s12282-013-0503-1","article-title":"Prevalence and differentiation of hereditary breast and ovarian cancers in Japan","volume":"22","author":"Nakamura","year":"2015","journal-title":"Breast Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wong, E.S.Y., Shekar, S., Chan, C.H.T., Hong, L.Z., Poon, S.-Y., Silla, T., Lin, C., Kumar, V., Davila, S., and Voorhoeve, M. (2015). Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134408"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","article-title":"Hereditary breast and ovarian cancer (HBOC): Review of its molecular characteristics, screening, treatment, and prognosis","volume":"28","author":"Yoshida","year":"2021","journal-title":"Breast Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.18632\/oncotarget.26852","article-title":"Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X","volume":"10","author":"Yoshida","year":"2019","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-019-05152-9","article-title":"High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer","volume":"175","author":"Bick","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.21037\/gs-20-596","article-title":"The clinicopathological and MRI features of patients with BRCA1\/2 mutations in familial breast cancer","volume":"10","author":"You","year":"2021","journal-title":"Gland. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S1470-2045(21)00580-5","article-title":"Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: An observational cohort study","volume":"22","author":"Khincha","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"P\u00eerlog, L.M., P\u0103tr\u0103\u0219canu, A.A., Militaru, M.S., and C\u0103tan\u0103, A. (2024). Insights into Clinical Disorders in Cowden Syndrome: A Comprehensive Review. Medicina, 60.","DOI":"10.3390\/medicina60050767"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Milella, M., Falcone, I., Conciatori, F., Cesta Incani, U., Del Curatolo, A., Inzerilli, N., Nuzzo, C.M., Vaccaro, V., Vari, S., and Cognetti, F. (2015). PTEN: Multiple Functions in Human Malignant Tumors. Front. Oncol., 16.","DOI":"10.3389\/fonc.2015.00024"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000312656","article-title":"Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies","volume":"78","author":"Fabi","year":"2010","journal-title":"Oncology"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kole, C., Charalampakis, N., Sakellariou, S., Papaxoinis, G., Apostolou, K.G., Machairas, N., Papanikolaou, I.S., and Schizas, D. (2022). Hereditary Diffuse Gastric Cancer: A 2022 Update. J. Pers. Med., 12.","DOI":"10.3390\/jpm12122032"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e247862","DOI":"10.1001\/jamanetworkopen.2024.7862","article-title":"CDH1 Genotype Exploration in Women With Hereditary Lobular Breast Cancer Phenotype","volume":"7","author":"Corso","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer Risks Associated with Germline PALB2 Pathogenic Variants: An International Study of 524 Families","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1245\/s10434-020-09158-2","article-title":"Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations","volume":"28","author":"Bergstrom","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-022-01052-8","article-title":"Breast cancer risks associated with missense variants in breast cancer susceptibility genes","volume":"14","author":"Dorling","year":"2022","journal-title":"Genome Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","article-title":"Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers","volume":"182","author":"Cragun","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.32572","article-title":"Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations","volume":"126","author":"Vysotskaia","year":"2020","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13058-018-0935-9","article-title":"BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer","volume":"20","author":"Hauke","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-017-4181-0","article-title":"Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients","volume":"163","author":"Crawford","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","article-title":"Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1\/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1\/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer","volume":"22","author":"Kapoor","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S1470-2045(19)30489-9","article-title":"MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc)","volume":"20","author":"Narod","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S1470-2045(19)30275-X","article-title":"MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): A multicentre, randomised, controlled trial","volume":"20","author":"Saadatmand","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients with Hereditary Cancer Syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/cam4.1519","article-title":"Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer","volume":"7","author":"Elsayegh","year":"2018","journal-title":"Cancer Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1245\/s10434-019-07595-2","article-title":"Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing","volume":"26","author":"Chang","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kwong, A., Ho, C.Y.S., Shin, V.Y., Au, C.H., Chan, T.L., and Ma, E.S.K. (2022). How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?. BMC Med. Genom., 15.","DOI":"10.1186\/s12920-022-01270-4"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3390\/curroncol31060256","article-title":"The Development and Evaluation of Novel Patient Educational Material for a Variant of Uncertain Significance (VUS) Result in Hereditary Cancer Genes","volume":"31","author":"Cragun","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3390\/curroncol29030171","article-title":"The Breast Cancer Screening and Timing of Breast MRI-Experience in a Genetic High-Risk Screening Clinic in a Comprehensive Cancer Center","volume":"29","author":"Wang","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s12282-020-01103-1","article-title":"Current status of breast cancer screening in high-risk women in Japan","volume":"28","author":"Tozaki","year":"2021","journal-title":"Breast Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.annonc.2021.08.2154","article-title":"Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD","volume":"32","author":"Hodgson","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.annonc.2021.09.003","article-title":"Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial","volume":"32","author":"Loibl","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1245\/s10434-022-12329-y","article-title":"Homologous Recombination Deficiency in Triple-Negative Breast Cancer: Potential Benefit of a New Target","volume":"30","author":"Nakamura","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-19-0664","article-title":"Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1\/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis","volume":"26","author":"Telli","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types","volume":"2","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41523-021-00315-8","article-title":"Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families","volume":"7","author":"Matis","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Creeden, J.F., Nanavaty, N.S., Einloth, K.R., Gillman, C.E., Stanbery, L., Hamouda, D.M., Dworkin, L., and Nemunaitis, J. (2021). Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08863-9"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Min, A., Kim, K., Jeong, K., Choi, S., Kim, S., Suh, K.J., Lee, K.-H., Kim, S., and Im, S.-A. (2020). Homologous repair deficiency score for identifying breast cancers with defective DNA damage response. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-68176-y"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/tbj.13969","article-title":"Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer","volume":"26","author":"Wood","year":"2020","journal-title":"Breast J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1038\/s41467-022-34109-8","article-title":"Reversion mutations in germline BRCA1\/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies","volume":"13","author":"Schram","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/cas.16033","article-title":"BRCA1\/2 reversion mutations in a pan-cancer cohort","volume":"115","author":"Nakamura","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1007\/s00330-018-5975-0","article-title":"Pilot study of rapid MR pancreas screening for patients with BRCA mutation","volume":"29","author":"Corrias","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.2147\/CMAR.S211151","article-title":"BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects","volume":"12","author":"Wong","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/j.cgh.2021.04.013","article-title":"Germline Cancer Susceptibility Gene Testing in Unselected Patients with Colorectal Adenocarcinoma: A Multicenter Prospective Study","volume":"20","author":"Uson","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cncr.33866","article-title":"Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center","volume":"128","author":"Arun","year":"2022","journal-title":"Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jgc4.1374","article-title":"Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors","volume":"30","author":"Berliner","year":"2021","journal-title":"J. Genet. Couns."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajhg.2020.09.001","article-title":"Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk","volume":"107","author":"Kramer","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2119084","DOI":"10.1001\/jamanetworkopen.2021.19084","article-title":"Generalizability of Polygenic Risk Scores for Breast Cancer Among Women with European, African, and Latinx Ancestry","volume":"4","author":"Liu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1038\/s41467-020-19966-5","article-title":"The role of polygenic risk and susceptibility genes in breast cancer over the course of life","volume":"11","author":"Mars","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41416-021-01550-3","article-title":"The current status of risk-stratified breast screening","volume":"126","author":"Clift","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaoncol.2019.3820","article-title":"Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines","volume":"6","author":"Gierach","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"McWilliams, L., Woof, V.G., Donnelly, L.S., Howell, A., Evans, D.G., and French, D.P. (2020). Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders\u2019 views on a low-risk breast screening pathway. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07158-9"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.3390\/curroncol30050366","article-title":"Outcomes of a Multidisciplinary Team in the Management of Patients with Early-Stage Breast Cancer Undergoing Neoadjuvant Chemotherapy at a Community Cancer Center","volume":"30","author":"Bhardwaj","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Kurniasih, D.A.A., Setiawati, E.P., Pradipta, I.S., and Subarnas, A. (2022). Interprofessional collaboration in the breast cancer unit: How do healthcare workers see it?. BMC Womens Health, 22.","DOI":"10.1186\/s12905-022-01818-7"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Milana, F., Famularo, S., Luberto, A., Rimassa, L., Scorsetti, M., Comito, T., Pressiani, T., Franzese, C., Poretti, D., and Di Tommaso, L. (2022). Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients. Cancers, 14.","DOI":"10.3390\/cancers14163952"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1097\/MS9.0000000000000914","article-title":"The effect of multidisciplinary team on survival rates of women with breast cancer: A systematic review and meta-analysis","volume":"85","author":"Pangarsa","year":"2023","journal-title":"Ann. Med Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(96)02482-8","article-title":"Benefits from specialised cancer care","volume":"348","author":"Selby","year":"1996","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"230157","DOI":"10.1183\/16000617.0157-2023","article-title":"Multidisciplinary meeting review in nonsmall cell lung cancer: A systematic review and meta-analysis","volume":"33","author":"Stirling","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bju.15856","article-title":"The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer","volume":"131","author":"Walraven","year":"2023","journal-title":"BJU Int."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/90\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:27:49Z","timestamp":1760027269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/90"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["curroncol32020090"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32020090","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}